• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常规门诊环境中狼疮活动度测量方法的有效性和可靠性。

Validity and reliability of lupus activity measures in the routine clinic setting.

作者信息

Petri M, Hellmann D, Hochberg M

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

J Rheumatol. 1992 Jan;19(1):53-9.

PMID:1556700
Abstract

As part of a cohort study of 150 patients with systemic lupus erythematosus (SLE), we investigated the validity and reliability of several indices of lupus activity, including the UCSF/JHU Lupus Activity Index (LAI), the SLE Disease Activity Index (SLEDAI), and a simple Core Index combining common elements. Validity was assessed by measuring correlations of these indices at the first cohort visit with the physician's global assessment (PGA) of SLE activity. The correlation of M-LAI (LAI modified so as not to contain PGA) and SLEDAI with PGA was 0.64 (95% CI 0.50, 0.70) and 0.55 (95% CI 0.42, 0.64), respectively. Reliability was assessed in a study of 6 patients seen twice, one week apart, by 9 physicians. The interrater reliability and test-retest reliability was greater for LAI (or M-LAI) than for SLEDAI. The Core Index performed better in its correlation with PGA (R = 0.78), although it contained no treatment data or serologic tests. Its interrater reliability and test-retest reliability were comparable with LAI. We conclude that (1) all indices have high validity; (2) LAI and the Core Index have higher reliability; and (3) these indices can be readily assimilated into routine clinic practice.

摘要

作为一项针对150例系统性红斑狼疮(SLE)患者的队列研究的一部分,我们调查了几种狼疮活动指数的有效性和可靠性,包括加州大学旧金山分校/约翰·霍普金斯大学狼疮活动指数(LAI)、SLE疾病活动指数(SLEDAI)以及一个结合了常见要素的简单核心指数。通过在队列首次访视时测量这些指数与医生对SLE活动的整体评估(PGA)之间的相关性来评估有效性。改良后不包含PGA的M-LAI与PGA的相关性为0.64(95%可信区间0.50, 0.70),SLEDAI与PGA的相关性为0.55(95%可信区间0.42, 0.64)。在一项由9名医生对6例患者进行的研究中评估了可靠性,这些患者在相隔一周的时间内接受了两次检查。LAI(或M-LAI)的评分者间信度和重测信度高于SLEDAI。核心指数与PGA的相关性更好(R = 0.78),尽管它不包含治疗数据或血清学检查。其评分者间信度和重测信度与LAI相当。我们得出结论:(1)所有指数都具有高有效性;(2)LAI和核心指数具有更高的可靠性;(3)这些指数可以很容易地应用于日常临床实践。

相似文献

1
Validity and reliability of lupus activity measures in the routine clinic setting.常规门诊环境中狼疮活动度测量方法的有效性和可靠性。
J Rheumatol. 1992 Jan;19(1):53-9.
2
Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.系统性红斑狼疮中5种活动指数的有效性及对变化的敏感性比较。
J Rheumatol. 2000 Mar;27(3):664-70.
3
The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.修订后的系统性狼疮活动度量表、墨西哥系统性红斑狼疮疾病活动指数(SLEDAI)以及改良的SLEDAI-2K是用于测量系统性红斑狼疮疾病活动度的合适工具。
J Rheumatol. 2004 Oct;31(10):1934-40.
4
Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.健康效用测量方法能否用于狼疮研究?4种效用指数的比较验证与可靠性研究。
J Rheumatol. 1999 Jun;26(6):1285-90.
5
A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus.系统性红斑狼疮疾病活动指数(SLEDAI)的可靠性研究
J Rheumatol. 1993 Apr;20(4):657-60.
6
Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale.孕期系统性红斑狼疮活动度的测量:孕期狼疮活动指数量表的验证
Arthritis Rheum. 2004 Feb 15;51(1):78-82. doi: 10.1002/art.20081.
7
Patterns of disease activity in systemic lupus erythematosus.系统性红斑狼疮的疾病活动模式
Arthritis Rheum. 1999 Dec;42(12):2682-8. doi: 10.1002/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6.
8
Small changes in outpatients lupus activity are better detected by clinical instruments than by laboratory tests.门诊患者狼疮活动的微小变化通过临床检查比实验室检查能更好地检测出来。
J Rheumatol. 1995 Nov;22(11):2078-83.
9
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.系统性红斑狼疮患者的评估及狼疮疾病活动指数的应用。
Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708. doi: 10.1016/j.berh.2005.03.010.
10
Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices.系统性红斑狼疮疾病活动度的测量。3种临床指标的前瞻性验证。
J Rheumatol. 1992 Oct;19(10):1551-8.

引用本文的文献

1
Pain in systemic lupus erythematosus: emerging insights and paradigms.系统性红斑狼疮中的疼痛:新见解与范例
Nat Rev Rheumatol. 2025 Aug 26. doi: 10.1038/s41584-025-01290-1.
2
Relationship between hydroxychloroquine blood levels and lupus activity through the lens of the type 1 and type 2 lupus model: a cross-sectional study.从1型和2型狼疮模型角度看羟氯喹血药浓度与狼疮活动度的关系:一项横断面研究
Lupus Sci Med. 2025 Jun 30;12(1):e001531. doi: 10.1136/lupus-2025-001531.
3
Application of machine learning in assessing disease activity in SLE.
机器学习在评估系统性红斑狼疮疾病活动度中的应用。
Lupus Sci Med. 2025 Apr 8;12(1):e001456. doi: 10.1136/lupus-2024-001456.
4
Transitioning from Lupus Low Disease Activity State to remission in systemic lupus erythematosus: real-world evidence.系统性红斑狼疮从狼疮低疾病活动状态转变为缓解:真实世界证据
Front Immunol. 2025 Mar 20;16:1546306. doi: 10.3389/fimmu.2025.1546306. eCollection 2025.
5
Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort.一个大型跨国前瞻性狼疮队列中疾病发作和持续活动性疾病的频率及决定因素
ACR Open Rheumatol. 2025 Mar;7(3):e70007. doi: 10.1002/acr2.70007.
6
Infection-Associated Flares in Systemic Lupus Erythematosus.系统性红斑狼疮中的感染相关发作
Pathogens. 2024 Oct 26;13(11):934. doi: 10.3390/pathogens13110934.
7
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus.描述并分析系统性红斑狼疮患者不同低疾病活动状态亚组的特征和结局。
Lupus Sci Med. 2024 Sep 18;11(2):e001217. doi: 10.1136/lupus-2024-001217.
8
Belimumab in early systemic lupus erythematosus: A propensity score matching analysis.贝利尤单抗治疗早期系统性红斑狼疮:一项倾向评分匹配分析。
Immun Inflamm Dis. 2024 Aug;12(8):e1362. doi: 10.1002/iid3.1362.
9
Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE.解偶联干扰素及其干扰素特征可解释 SLE 的临床和转录亚群。
Cell Rep Med. 2024 May 21;5(5):101569. doi: 10.1016/j.xcrm.2024.101569. Epub 2024 May 13.
10
Immune and molecular landscape behind non-response to Mycophenolate Mofetil and Azathioprine in lupus nephritis therapy.狼疮性肾炎治疗中对霉酚酸酯和硫唑嘌呤无反应背后的免疫和分子格局。
Res Sq. 2024 Jan 12:rs.3.rs-3783877. doi: 10.21203/rs.3.rs-3783877/v1.